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ABSTRACT
Objective: This study sought to determine whether
changes in neurodevelopmental outcomes between 18
and 36 months of age were associated with prenatal
exposure to triptan medications, a class of 5-HT
receptor agonists used in the treatment of migraine.
Method: Using data from the Norwegian Mother and
Child Cohort Study, a prospective birth cohort that
includes nearly 40% of all pregnancies in Norway from
1999 to 2008, we identified 50 469 mother–child
dyads who met inclusion criteria and were present for
at least one follow-up assessment at 18 or 36 months
postpartum. Neurodevelopment was assessed using
the Child Behaviour Checklist, the Emotionality,
Activity, and Shyness Questionnaire, and the Ages and
Stages Questionnaire. We used generalised estimating
equations to evaluate change from 18 to 36 months for
children prenatally exposed to triptans, relative to
contrast groups, and used marginal structural models
with inverse probability of treatment and censoring
weights to address time-varying exposure and
confounding as well as loss to follow-up.
Results: Among eligible participants (n=50 469), 1.0%
used a triptan during pregnancy, 2.0% used triptans
prior to pregnancy only, 8.0% reported migraine without
triptan use and 89.0% had no history of migraine.
Children with prenatal triptan exposure had greater
increases in emotionality (r-RR 2.18, 95% CI 1.03 to
4.53) and activity problems (r-RR 1.70, 95% CI 1.02 to
2.8) compared to children born to mothers who
discontinued triptan use prior to pregnancy.
Conclusion: Prenatal triptan exposure was associated
with changes over time in externalising-type behaviours
such as emotionality and activity, but not with
internalising-type behaviours.
INTRODUCTION
Migraine is a chronic pain condition that
affects ∼20% of women of reproductive
age.1 2 Treatment options for migraine are
primarily pharmacologic and include anal-
gesic medications as well as triptans, which
are taken in response to an oncoming
migraine episode and act to prevent or
shorten the severity or duration of the
migraine attack. Triptans are class of sero-
tonin 5-HT1B, 5-HT1D and 5-HT1F receptor
agonists that act on smooth muscle as well as
the trigeminal cervical complex, and are the
most common prescription acute migraine
medication.3 To date, 10 studies have exam-
ined the safety of triptan use during preg-
nancy, but most of them have focused on
pregnancy and very early life outcomes.
Triptans have been associated with pre-
eclampsia, preterm birth and increased risk
of folate-deﬁcient anaemia, but not with
major congenital malformations.4–7 A recent
meta-analysis found no increased risk of
preterm birth or congenital malformation
associated with prenatal triptan exposure but
did note an increased risk of spontaneous
abortion.8 An additional review of migraine
treatment during pregnancy recommends
Strengths and limitations of this study
▪ Prospective, longitudinal cohort study with
extensive data on exposure to medications as
well as other confounders.
▪ Internationally recognised and extensively vali-
dated neurodevelopmental outcome measures.
▪ Longitudinal statistical analysis making use of
multiple outcome measurement.
▪ No information on confounding by migraine
severity or on dose or formulation of triptan
medication.
▪ As with all observational studies, cannot rule out
unmeasured confounding.
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that triptans may be used conservatively in pregnancy if
adequate pain relief is not achieved through acetamino-
phen alone.4
Despite the plausibility of triptans as a neurodevelop-
mental teratogen,9 10 studies of the effect of prenatal
triptan on childhood neurodevelopment have been
sparse. Our previous work found that prenatal exposure
to triptans was associated with an increased risk of exter-
nalising behaviour in 3-year-old children11 and no asso-
ciations with motor skills, communication or
temperament, after adjustment for migraine severity.12
No prior studies have examined changes in behaviour
over time following prenatal exposure to triptans. Since
brain development is a dynamic process, examining dif-
ferences in change over time may yield important
insights into the mechanism by which triptans affect the
developing brain.
Building on our previous research, this study aims to
quantify the effect of triptan use during pregnancy on
the differences in neurodevelopment outcomes from 18
to 36 months between children. Among neurodevelop-
mental outcomes associated with triptan use during
pregnancy, we also sought to determine whether timing
of triptan exposure (ﬁrst trimester, second/third trimes-
ter) is related to differences in change over time.
METHODS
Norwegian Mother and Child Cohort Study
Between 1999 and 2008, the Norwegian Institute of
Public Health invited women to participate in the
Norwegian Mother and Child Cohort Study (MoBa).13
Women were invited prior to their ﬁrst routine ultra-
sound appointment (gestational weeks 13–17). A total
of 108 841 women consented to participate (participa-
tion rate 42.7%), with 84.8% of the participants com-
pleting the 6-month postpartum questionnaire and
60.2% completing the 36-month postpartum question-
naire.14 15 Written informed consent was obtained from
all participants, and the Regional Committee for
Medical Research Ethics and the Norwegian Data
Inspectorate approved the study; this analysis was
granted an exemption from the University of
Massachusetts Medical School Institutional Review
Board. Data were taken from the quality-ensured Data
V.6, released by MoBa in 2012 and includes all children
born before 2009 for whom the age 3 years question-
naire was received by 4 May 2011; these data were
linked to the Medical Birth Registry of Norway
(MBRN) using participants’ 11-digit personal identiﬁca-
tion numbers. Details of selection into the study are
described in ﬁgure 1.
Exclusion criteria were as follows: infant not born
alive, multiple births, major congenital malformations or
chromosomal abnormalities, and indication of triptan
exposure where we were unable to determine whether
the triptan was taken prior to or during pregnancy. In
total, 7220 women were excluded. We included 59 468
mother–child dyads with complete outcome data at the
18-month and/or 36-month follow-up. We conducted a
complete case analysis in which dyads with missing data
on variables thought to be confounders were excluded,
leaving an analytic sample of 50 469 women, of which
14 790 had complete outcome data only at 18-month
follow-up, 6774 had complete data only at 36 months
and 28 905 had complete outcome data at 18 and
36 months. In analyses of timing of triptan exposure, we
included only 5484 women with a self-reported history
of migraine headache at the ﬁrst pregnancy
questionnaire.
Triptan exposure
Information on exposure to medications was gathered
prospectively from two prenatal (Q1-gestational week 17,
Q3-gestational week 30) and one postpartum (Q4–6
months postpartum) questionnaires. Women indicated
when they had taken a medication (during the
6 months before pregnancy, during weeks 0–4, 5–8, 9–12
and/or 13 or later for Q1, during weeks 13–16, 17–20,
21–24, 25–28 and/or 29 or later for Q3, and from week
30 until birth for Q4) and to write the name of the
medication in a text box. Medications were classiﬁed
according to the WHO Anatomical Therapeutic
Chemical (ATC) Classiﬁcation System.16 The ATC code
N02CC was used to determine triptan exposure. Triptan
medications were further classiﬁed into speciﬁc com-
pounds: N02CC01 (sumatriptan), N02CC02 (naratrip-
tan), N02CC03 (zolmitriptan), N02CC04 (rizatriptan),
N02CC05 (almotriptan), N02CC06 (eletriptan) and
N02CC07 (frovatriptan). No information was available
on formulation or dose.
Information on migraine was gathered prospectively
from pregnancy questionnaire 1, which asked whether
the woman had migraine within 6 months prior to preg-
nancy or during pregnancy, up to week 17 of pregnancy.
Four exposure groups were created: prenatal triptan
exposure, prepregnancy triptan use, migraine only and
population comparison.
Neurodevelopmental Outcomes
Child Behavior Checklist
The Child Behavior Checklist (CBCL) is a validated
measure of child behaviour widely used in clinical and
research practice; a shortened version, validated in a
Norwegian population, was used in MoBa.17 The exter-
nalising (‘attention problems’ and ‘aggressive behaviour’
subscales) and internalising (‘emotionally reactive’,
‘anxious/depressed’ and ‘somatic symptoms’ subscales)
domains were used. Standardised z-scores over or equal
to 1.50 on the CBCL measure were used as a clinically
relevant cut-off as recommended by Achenbach and
Rufﬂe.18 19 Children scoring over this cut-off had behav-
ioural problems (externalising or internalising) more
extreme than 94% of the sample.
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Emotionality, Activity and Shyness Temperament
Questionnaire
The Emotionality, Activity and Shyness Temperament
Questionnaire (EAS) measures four temperament
domains (emotionality, shyness, sociability and activity).
A substantial body of literature has linked early-
childhood temperament to later-life depression and
other psychiatric diagnoses.20 21 The shortened version
of the EAS used in the MoBa study was developed with
Norwegian social norms in mind and includes 12
descriptions (eg, “Your child likes to be with people”;
“Your child cries easily”), and parents are asked to rate
how well each statement applies to their child; in a
Norwegian sample, internal consistency (α) within each
scale ranged from 0.48 to 0.79.22 We calculated z-scores
based on the sample distribution of each domain.
Higher z-scores indicate greater parental endorsement
of each temperament trait (eg, more shy or more soci-
able) relative to parental reports of other children in the
sample. We additionally categorised scores to indicate
temperamental traits more extreme than 94% of the
sample (z-score ≥ 1.50).
Ages and Stages Questionnaire
The Ages and Stages Questionnaire (ASQ) is a parent-
completed questionnaire appropriate for children aged
from 4 months to 5 years. Deﬁcits detected by the ASQ
are predictive of school difﬁculties in older children,23
and ﬁne motor skills are highly predictive of later aca-
demic achievement.24 The abbreviated ASQ used in
MoBa includes questions about developmental mile-
stone attainment in three major categories: gross motor,
ﬁne motor, and communication; this shortened version
has been validated in a Norwegian population and had
excellent test–retest reliability and agreement between
parents and professional examiners.25 Scores on the
ASQ domains were highly skewed; to address this, we
categorised children at each time point as having pro-
blems in a given domain if they scored at or above the
94th centile in the sample, versus scoring below the 94th
centile. This categorisation is comparable to using a
z-score of ≥1.50 as a cut-off.
The CBCL, EAS and ASQ have all been validated in
children as young as 18 months. Complete information
on the neurodevelopmental outcomes used in this study,
Figure 1 Inclusion and
exclusion criteria.
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including procedures used for validation in the MoBa
cohort, and the questions selected for each instrument,
are available online.26
Concomitant medication use
We examined other pain medications and psychotropic
medications as potential confounders, acetaminophen,
opioids, non-steroidal anti-inﬂammatory drugs (NSAIDs),
antidepressants, benzodiazepines and anti-epileptics. All
comedications were categorised as ever versus never used
in pregnancy and prior to pregnancy.
Maternal characteristics
Maternal age, prepregnancy body mass index (BMI)
(underweight or <18.5 kg/m2, normal weight or 18.5–
25 kg/m2, or overweight, >25 kg/m2 according to WHO
guidelines), education (primary or secondary vs univer-
sity or higher), marital status (married or cohabiting vs
other), parity (multiparous vs primiparous) and depres-
sion history (yes or no) were all ascertained by self-
report on Q1. Maternal depressive and anxiety symp-
toms were measured by a validated short version of the
Hopkins Symptom Checklist (SCL).27 Smoking (ever
during pregnancy vs not during pregnancy) and alcohol
use (ever during pregnancy vs not during pregnancy)
were ascertained by combining information from self-
report as well as linkage to the MBRN.
Loss to follow-up
We observed substantial loss to follow-up at the 18-month
and 36-month questionnaires (57.3% present at 18 and
36 months, 29.3% at 18 months only and 13.4% at 36
months only). To adjust for the potential for selection
bias due to measured predictors of attrition, we con-
structed stabilised inverse probability of censoring weights
(IPCW) and conducted weighted analyses.28
Data analysis
The purpose of this analysis was to examine differences
in neurodevelopmental changes over time associated
with prenatal triptan exposure. First, we examined
descriptive statistics across the four main exposure
groups and compared absolute percentages (for categor-
ical measures); we considered a difference of >5% to be
meaningful. Next, we used generalised estimating equa-
tions (GEE) to ﬁt generalised linear models, specifying a
binomial distribution and a log link, that included ﬁxed
effects for exposure group (prenatal triptan exposure,
prepregnancy triptan use, migraine only and population
comparison), time (18 and 36 months) and their inter-
action. GEE models were selected for their approach to
missing outcome data (using all available observations,
rather than casewise deletion for observations present
only at a single time point), as well as their ability to
model covariation using ﬂexible covariance structures
among repeated measures. Based on comparisons
between the empirical and model-based covariance
matrices, we selected an exchangeable covariance
structure for all models. The resulting estimates repre-
sent the change in risk (r-RR) of having a clinically
meaningful neurodevelopmental outcome between 18
and 36 months of age for children with prenatal triptan
exposure, relative to each contrast group (prepregnancy
triptan use only, migraine only and population compari-
son), with 95% CIs calculated using robust SEs. Models
were adjusted for maternal characteristics (age, prepreg-
nancy BMI, parity, marital status, education, smoking or
alcohol use in pregnancy, depression symptom severity)
and concomitant medication use (NSAIDs, acetamino-
phen, opioids, antidepressants). To assist in the inter-
pretation of the data, we used model-based predicted
probability of outcome at 18 and 36 months to create
line graphs of the change in outcome over time for each
exposure group. Examination of graphs was useful
because the r-RR of >1 could be a result of qualitatively
different phenomena (eg, greater increased risk over
time in triptan group relative to increased risks observed
in the contrast group, increased risk in the triptan users
group and decreased risk in the comparison group).
Finally, for the neurodevelopmental outcomes that were
associated with any triptan use during pregnancy, we devel-
oped marginal structural models (MSM) to understand
the effect of exposure timing on the difference in change
of the outcome from 18 to 36 months. We ﬁt MSM with
stabilised inverse probability of treatment weights (IPTW)
to adjust for measured confounding by baseline character-
istics (maternal age, prepregnancy BMI, sociodemo-
graphic variables), time-invariant predictors (smoking and
alcohol use during pregnancy, folate supplementation,
maternal depression severity) as well as time-varying con-
founders (other medication use, including acetamino-
phen, NSAIDs, opioids and antidepressants). The MSM
approach results in unbiased effect estimates under
assumptions of exchangeability and positivity, and allows
for appropriate adjustment for the effects of confounders
that are also mediators.29 30 We created the IPTW via logis-
tic regression at each exposure time point (prepregnancy,
ﬁrst trimester, second/third trimester) created an IPTW
equal to the product of the weight from each time point.
The product of IPTW and IPCW was used as the total
MSM weight, to account for measured confounding and
loss to follow-up. Weighted GEE models were then ﬁt
within the migraine-only group. Results are given as the
change in risk ratio over time (r-RR) for triptan exposure
at each time point (prepregnancy, ﬁrst trimester, second/
third trimester) relative to no exposure during that time,
with 95% CIs estimated using robust SEs to account for
clustering induced by weighting. For analyses conducted
in the ﬁrst and second steps, we interpreted a signiﬁcant
time-by-group interaction (95% CI that did not include 1)
to be indicative of a difference in change between expos-
ure groups, from 18 to 36 months of follow-up.
RESULTS
This study included 50 469 women, of whom 1.0%
reported using a triptan at least once during pregnancy,
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2.0% used triptans prior to pregnancy only and 8.0%
had a history of migraine with no use of triptans.
Among the 5484 women with history of migraine
(10.9% of the total sample), 27.1% used triptans prior
to pregnancy, 6.9% reported use during the ﬁrst trimes-
ter and 3.1% reported use during the second or third
trimester.
Women who reported triptan use during pregnancy
differed little from comparison groups in demographic
characteristics; age, prepregnancy BMI, parity, educa-
tional attainment, smoking during pregnancy and folate
supplementation were similar across groups. However,
women who used triptans during pregnancy had higher
depression and anxiety symptom scores than women
who discontinued triptan use (0.16 vs 0.03). In addition,
women with triptan use during pregnancy were more
likely to use other medications at higher rates during
pregnancy compared to women who discontinued
triptan use, including opioids (13.3% vs 4.6%), acet-
aminophen (78.2% vs 69.8%) and NSAIDs (22.0% vs
10.1%) (table 1).
The Externalising Behaviours subscale of the CBCL,
as well as the Emotionality and Activity subscales of the
EAS, describes a set of behaviours characterised by
increased activity, aggression and emotional reactivity.
Children whose mothers used triptans during pregnancy
had substantial increased risk of high emotionality com-
pared to static or decreased emotionality in children
whose mothers used triptans only prior to pregnancy
(r-RR 2.18, 95% CI 1.03 to 4.53) as well as those with a
history of migraine without triptan use (r-RR 2.51, 95%
CI 1.27 to 4.90) and a migraine-free population com-
parison group (r-RR 2.16, 95% CI 1.14 to 2.14) (table 2,
ﬁgure 2). When we examined the association of timing
of triptan exposure within the group of women with
migraine using MSM with inverse probability weights,
the r-RR estimate for ﬁrst trimester exposure relative to
no ﬁrst trimester exposure was 1.54 (95% CI 0.57 to
4.13) and the r-RR estimate for second/third trimester
exposure relative to no second/third trimester exposure
was 2.41 (95% CI 0.71 to 8.20) (table 3). We also
observed differences in the rate of change for activity:
children with prenatal triptan exposure had lesser
decreases in activity from 18 to 36 months, relative to
the prepregnancy (r-RR 1.70, 95% CI 1.02 to 2.80),
migraine only (r-RR 1.57, 95% CI 1.04 to 2.36) and
population comparison (r-RR 1.67, 95% CI 1.14 to 2.14)
groups (table 2). Examining the association between
outcome and timing of exposure revealed that the r-RR
estimate for second/third trimester exposure relative to
no second/third trimester exposure was 1.37 (95% CI
0.46 to 4.10) (table 3). Externalising behaviour in chil-
dren with prenatal triptan exposure, as measured by the
CBCL, remained elevated compared to all contrast
groups but did not show evidence of increase or
decrease over time (table 2, ﬁgure 2).
The Internalising Behaviour subscale of the CBCL,
along with the Shyness and Sociability subscales of the
EAS, describes a set of symptoms characterised by
anxiety, shyness and withdrawal. Shyness and sociability
were not associated with use of triptans during preg-
nancy (table 2, see online supplementary ﬁgure S1).
We saw no differences in change of risk for gross
motor, ﬁne motor or communication problems from 18
to 36 months for children with prenatal triptan expos-
ure, relative to any comparison group (table 2, see
online supplementary ﬁgure S2).
DISCUSSION
We observed several neurodevelopmental domains in
which change in neurodevelopment was substantially dif-
ferent for children with prenatal triptan exposure,
including emotionality and activity; these domains
appear to be associated with prenatal triptan exposure
speciﬁcally, rather than migraine. There were no overall
differences in internalising behaviours and shyness and
motor problems or communication problems associated
with either triptan exposure or migraine.
Our previous work, which was the ﬁrst to report on
neurodevelopmental sequelae of prenatal triptan expos-
ure, indicated that exposed children had higher rates of
externalising problems at 36 months than those without
prenatal exposure.11 The ﬁndings from the current
study suggest that these elevated rates of externalising
behaviour remain relatively stable between 18 and
36 months; additionally, the observed increases in emo-
tionality and activity describe a consistent proﬁle of tem-
peramental and behavioural dysregulation associated
with prenatal triptan exposure. Several studies in the
animal literature suggest that 5-HT1B and 5-HT1D recep-
tor expression modiﬁes fetal brain development,10 31
providing a plausible biological mechanism for this
observed association.
A possible alternative explanation for our ﬁndings is
that women who used triptans in pregnancy had the
most severe migraine, whereas women who discontinued
triptan use prior to pregnancy and women with
migraine who did not use triptans had less severe illness.
Our prior work found that underlying migraine severity
explained some, but not all, of the observed associa-
tions,12 and that confounding by migraine severity
would have to be very strong to fully explain our ﬁnd-
ings.11 Therefore, while we cannot rule out confounding
by indication, it is unlikely to fully explain these results,
which suggest a distinct proﬁle for children with pre-
natal exposure to triptans in which changes in
externalising-type behaviours from 18 to 36 months were
markedly different from all comparison groups.
The prevalence of externalising problems among chil-
dren with prenatal triptan exposure was elevated at
18 months and remained relatively stable at 36 months,
while the prevalence of emotionality and activity
increased from 18 to 36 months in children with pre-
natal exposure, compared to all contrast groups.
Emotionality, in the context of the Emotionality, Activity
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and Shyness Questionnaire, includes items that tap emo-
tional reactivity, while items in the Activity subscale ask
about higher levels of physical activity. Of potential inter-
est is the fact that the emotionality and activity domains,
as well as the externalising behaviour domain, ask parents
to report on observable behaviours in their children,
such as temper explosions, hyperactivity and coordination
problems, whereas the sociability and shyness domains, as
well as internalising behaviours, ask parents to report on
their child’s internal state. Parents are better reporters of
externalising symptoms, whereas children are better
reporters of internalising symptoms.32 Future studies
should include replicating these ﬁndings in an older
cohort of children, in which child self-report and clinical
Table 1 Maternal and pregnancy characteristics
Migraine No migraine
Triptans in
pregnancy
Triptans prior to
pregnancy
No triptan
history
Population
comparison
N=495 N=1002 N=4050 N=44 922
Age in years (mean, SD) 30.9 (4.3) 30.4 (4.1) 30.2 (4.5) 30.3 (4.4)
BMI (kg/m2) (N, %)
<18.5 12 (2.4) 25 (2.5) 145 (3.6) 1216 (2.7)
18.5–25 307 (62.0) 608 (60.7) 2491 (61.5) 29 747 (66.2)
>25 176 (35.6) 369 (36.8) 1414 (34.9) 13 959 (31.1)
Multiparous 254 (51.3) 467 (46.6) 2204 (54.4) 24 467 (54.5)
Married or cohabitating 474 (95.8) 980 (97.8) 3922 (96.8) 43 761 (97.4)
Mother education
Primary or secondary 165 (33.3) 339 (33.8) 1533 (37.9) 14 511 (32.3)
University or higher 330 (66.7) 663 (66.2) 2517 (62.2) 30 411 (67.7)
Smoking during pregnancy 57 (11.5) 118 (11.8) 552 (13.6) 5236 (11.7)
Alcohol during pregnancy 95 (19.2) 146 (14.6) 623 (15.4) 7506 (16.7)
Folate supplementation 299 (60.4) 618 (61.7) 2359 (58.3) 26 462 (58.9)
Multivitamin supplementation 186 (37.6) 426 (42.5) 1610 (39.8) 16 661 (37.1)
Migraine preventive therapy 8 (1.6) 21 (2.1) 22 (0.5) 0 (0.0)
Opioids
Prepregnancy 40 (8.1) 52 (5.2) 208 (5.1) 609 (1.4)
In pregnancy 66 (13.3) 46 (4.6) 188 (4.6) 631 (1.4)
Acetaminophen
Prepregnancy 233 (47.1) 475 (47.4) 1794 (44.3) 11 474 (25.5)
In pregnancy 387 (78.2) 699 (69.8) 2596 (34.1) 19 331 (43.0)
NSAIDs
Prepregnancy 109 (22.0) 247 (24.7) 938 (23.1) 4450 (9.9)
In pregnancy 109 (22.0) 101 (10.1) 509 (12.6) 2652 (5.9)
Antidepressants
Prepregnancy 24 (4.9) 48 (4.8) 158 (3.9) 1042 (2.3)
In pregnancy 11 (2.2) 11 (1.1) 67 (1.7) 426 (1.0)
Anticonvulsants
Prepregnancy 2 (0.4) 7 (0.7) 10 (0.3) 41 (0.1)
In pregnancy 1 (0.2) 3 (0.3) 13 (0.3) 86 (0.2)
Benzodiazepines
Prepregnancy 8 (1.6) 13 (1.3) 38 (0.9) 240 (0.5)
In pregnancy 8 (1.6) 5 (0.5) 19 (0.5) 165 (0.4)
Maternal depressive/anxiety symptoms*
(mean, SD)
0.16 (1.70) 0.03 (1.84) 0.23 (1.88) −0.12 (1.63)
Pre-eclampsia 33 (6.7) 47 (4.7) 170 (4.2) 1536 (3.4)
Small for gestational age† 35 (7.1) 65 (6.5) 269 (6.6) 2737 (6.1)
Apgar 5 (<7)‡ 7 (1.4) 9 (0.9) 30 (0.7) 415 (0.9)
Preterm§ 19 (3.8) 45 (4.5) 193 (4.8) 2026 (4.5)
Low birth weight¶ 11 (2.2) 24 (2.4) 108 (2.7) 1047 (2.3)
Numbers given are frequencies and percents, unless otherwise indicated.
*Average z-score from the SCL; higher positive scores indicate more depressive symptoms.
†Small for gestational age defined as weight below the 10th centile for gestational age.
‡Number and per cent of children with a 5-min Apgar score of <7.
§Preterm birth defined as birth before the 37th week of gestation.
¶Low birth weight defined as weight at birth below 2500 g, regardless of the gestational age.
BMI, body mass index; NSAIDs, non-steroidal anti-inflammatory drugs; SCL, Symptom Checklist.
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Table 2 Change in neurodevelopmental outcome from 18 to 36 months: change over time for prenatal triptan exposure,
relative to prepregnancy triptan use, migraine only and population comparison
Per cent
(18 months )†
Per cent
(36 months)
Unadjusted
Multivariable
adjusted*
r-RR‡ 95% CI r-RR 95% CI
CBCL externalising behaviour
Prenatal triptan use 11.0 10.0
Versus prepregnancy triptans only 7.8 6.5 1.11 0.70 to 1.73 1.11 0.70 to 1.75
Versus migraine only 8.1 7.6 0.99 0.69 to 1.43 1.00 0.70 to 1.43
Versus population comparison 7.7 6.5 1.11 0.79 to 1.54 1.11 0.79 to 1.54
EAS emotionality
Prenatal triptan use 3.2 6.3
Versus prepregnancy triptans only 5.3 4.7 2.18 1.03 to 4.57 2.18 1.03 to 4.53
Versus migraine only 5.1 3.9 2.51 1.28 to 4.90 2.51 1.27 to 4.90
Versus population comparison 5.2 4.7 2.18 1.14 to 4.10 2.16 1.14 to 4.10
EAS activity
Prenatal triptan use 9.2 8.3
Versus prepregnancy triptans only 9.7 4.7 1.68 1.02 to 2.80 1.70 1.02 to 2.80
Versus migraine only 9.8 5.3 1.57 1.05 to 2.34 1.57 1.04 to 2.36
Versus population comparison 9.8 5.1 1.67 1.14 to 2.41 1.67 1.14 to 2.42
CBCL internalizing behaviour
Prenatal triptan use 8.1 9.5
Versus prepregnancy triptans only 6.2 10.8 0.70 0.41 to 1.16 0.69 0.41 to 1.14
Versus migraine only 8.7 10.5 1.01 0.66 to 1.57 1.02 0.66 to 1.57
Versus population comparison 7.5 8.1 1.14 0.75 to 1.72 1.12 0.74 to 1.70
EAS shyness
Prenatal triptan use 4.9 12.3
Versus prepregnancy triptans only 3.5 9.6 0.93 0.53 to 1.65 0.92 0.52 to 1.63
Versus migraine only 4.0 7.7 1.30 0.81 to 2.08 1.30 0.81 to 2.08
Versus population comparison 4.5 8.1 1.40 0.91 to 2.16 1.40 0.91 to 2.16
EAS sociability
Prenatal triptan use 8.8 6.3
Versus prepregnancy triptans only 6.8 6.4 0.77 0.45 to 1.38 0.78 0.44 to 1.38
Versus migraine only 9.3 6.1 1.12 0.69 to 1.80 1.13 0.70 to 1.82
Versus population comparison 8.0 5.7 1.02 0.65 to 1.62 1.03 0.65 to 1.63
ASQ gross motor
Prenatal triptan use 1.6 1.2
Versus prepregnancy triptans only 3.3 3.0 0.86 0.23 to 3.20 0.86 0.23 to 3.19
Versus migraine only 2.3 3.0 0.58 0.16 to 2.02 0.58 0.17 to 2.03
Versus population comparison 2.3 3.1 0.55 0.16 to 1.87 0.55 0.16 to 1.88
ASQ fine motor
Prenatal triptan use 13.9 9.5
Versus prepregnancy triptans only 11.6 9.4 0.84 0.52 to 1.36 0.85 0.52 to 1.37
Versus migraine only 11.5 9.2 0.85 0.56 to 1.28 0.85 0.56 to 1.29
Versus population comparison 11.8 10.4 0.78 0.52 to 1.13 0.77 0.52 to 1.14
ASQ communication
Prenatal triptan use 3.4 4.6
Versus prepregnancy triptans only 4.1 4.5 1.20 0.55 to 2.64 1.22 0.56 to 2.68
Versus migraine only 3.8 5.2 0.96 0.48 to 1.93 0.97 0.48 to 1.95
Versus population comparison 4.1 5.0 1.09 0.56 to 2.16 1.12 0.57 to 2.19
*Models are adjusted for maternal age, prepregnancy BMI, parity, marital status, education, smoking or alcohol use during pregnancy, SCL
depression/anxiety severity score and concomitant medication use during pregnancy (acetaminophen, opioids, NSAIDs, antidepressants).
†Per cent is the per cent with outcome, respectively, at each measurement (18 and 36 months postpartum): for example, at 18 months, 11%
of children with prenatal triptan exposure had externalising symptoms at or above a z-score of 1.50, compared with 7.8% of children whose
mothers used triptans prior to pregnancy.
‡r-RR is the group-by-time interaction coefficient from the generalised estimating equation model; it is the difference in change from 18 to
36 months for prenatal triptan exposure, relative to each contrast group.
ASQ, Ages and Stages Questionnaire; BMI, body mass index; CBCL, Child Behaviour Checklist; EAS, Emotionality, Activity and Shyness
Temperament Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs; r-RR, ratio of risk ratios; SCL, Symptom Checklist.
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observation of psychological or behavioural problems are
available.
The results of this study have important implications
for clinicians who may see children born to mothers with
migraine headache. Numerous studies have shown that
early-childhood emotional and behavioural problems are
predictive of academic and emotional difﬁculties in ado-
lescence,33–36 but that early intervention can effectively
Figure 2 Changes from 18 to 36 months for externalising-type behaviours.
Table 3 Change in neurodevelopmental outcome from 18 to 36 months: change over time associated with timing of triptan
exposure, within migraine-only sample (N=5484)
Per cent (8 months)† Per cent (36 months)
Unadjusted MSM*
r-RR‡ 95% CI r-RR 95% CI
CBCL externalising behaviour
Prepregnancy 8.4 7.5 0.94 0.67 to 1.30 0.90 0.64 to 1.25
First trimester 11.6 11.1 1.16 0.73 to 1.86 1.01 0.56 to 1.80
Second/third trimester 10.7 9.8 0.96 0.48 to 1.91 0.50 0.17 to 1.48
EAS emotionality
Prepregnancy 4.7 4.7 1.07 0.69 to 1.67 1.07 0.68 to 1.67
First trimester 3.8 5.6 1.43 0.58 to 3.51 1.54 0.57 to 4.13
Second/third trimester 4.0 7.1 1.52 0.48 to 4.85 2.41 0.71 to 8.20
EAS activity
Prepregnancy 9.6 5.7 0.90 0.63 to 1.28 0.88 0.61 to 1.28
First trimester 9.3 8.9 1.56 0.90 to 2.71 1.98 0.90 to 4.34
Second/third trimester 9.4 10.7 1.56 0.76 to 3.21 1.37 0.46 to 4.10
*Per cent is the per cent with outcome at each measurement (18 and 36 months postpartum), among those with exposure at each time point
(eg, per cent with externalising problems at 18 months with prenatal triptan use={(75/1002)×100}=7.49%. Windows of triptan exposure are not
mutually exclusive).
†r-RR is the group-by-time interaction coefficient from the generalised estimating equation model; it is the difference in change from 18 to
36 months for each group, relative to no exposure during that time point.
‡Models are weighted by the product of stabilised IPCW and IPTW; IPCW is the probability of dropout, conditional on maternal age, prepregnancy
BMI, marital status, parity, migraine history and use of triptans prior to and during pregnancy. IPTW includes baseline covariates (maternal age,
prepregnancy BMI, sociodemographic variables), time-invariant predictors (smoking and alcohol use during pregnancy, folate supplementation,
maternal depression severity), time-varying concomitant medication use (acetaminophen, NSAIDs, opioids, antidepressants) and treatment history
(triptan use).
BMI, body mass index; CBCL, Child Behaviour Checklist; EAS, Emotionality, Activity and Shyness Temperament Questionnaire; IPCW, inverse
probability of censoring weight; IPTW, inverse probability of treatment weight; MSM, marginal structural models; r-RR, ratio of risk ratios.
8 Wood ME, et al. BMJ Open 2016;6:e011971. doi:10.1136/bmjopen-2016-011971
Open Access
reduce these problems.37 38 Children whose mothers
have a history of migraine, and particularly those whose
mothers took triptans during pregnancy, may beneﬁt
from additional monitoring and potentially, treatment.
There are several important limitations to consider
when evaluating the ﬁndings from this study. First, MoBa
does not collect information on migraine severity, and
women with more severe migraine are more likely to use
triptans. In our previous research, we carried out sensi-
tivity analyses to examine the potential impact of
unmeasured confounding by migraine severity11 as well
as using an external validation study to calibrate effect
estimates12 to address this source of confounding, and
found that migraine severity would have to be an
extremely strong confounder to fully explain our results.
However, confounding by indication is difﬁcult to
control39 and cannot be ruled out as an explanation for
the observed results. Second, no information was avail-
able on triptan formulation or dose; additionally, we had
insufﬁcient power to analyse speciﬁc triptans. Triptans
have different pharmacokinetic properties and afﬁnities
for subclasses of serotonin receptors,40 and considering
these medications as a class may elide important infor-
mation on compound-speciﬁc risks. Exposure misclassiﬁ-
cation is possible; however, it is unlikely to be differential
with respect to outcome, and so is more likely to have
produced bias towards the null, as has been shown in
previous validation studies in the MoBa cohort.41
These limitations are balanced by important strengths:
ﬁrst, we used advanced analytic methods to appropri-
ately adjust for time-varying confounding by concomi-
tant medication use. Triptan exposure changes over
time, and women who use triptans in pregnancy also use
many other medications, several of which have previously
been associated with neurodevelopmental problems in
children.42–44 Failure to appropriately adjust for these
medications may result in incorrectly attributing effects to
triptan exposure that are in fact due to other medica-
tions. Our study was set in a large, prospective birth
cohort with data available on over-the-counter and pre-
scription medication use, allowing for careful consider-
ation of concomitant medication use, as well as other
important confounders such as severity of maternal
depressive and anxiety symptoms.
This study suggests that prenatal exposure to migraine
and triptans may be associated with neurodevelopmental
problems in children. However, these ﬁndings and our
related work are based on a single cohort and should be
replicated in other cohorts before clinical recommenda-
tions for treatment of migraine in pregnancy are changed.
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